Overview
Description
Denali Therapeutics Inc. is a biotechnology company focused on discovering and developing therapeutic interventions for neurodegenerative diseases. The primary aim of the company is to combat disorders linked to degeneration of the nervous system, such as Alzheimer's, Parkinson's, and ALS, by targeting and addressing underlying mechanisms of these diseases. Denali Therapeutics employs a unique engineering-driven approach, leveraging its deep understanding of biological pathways to create therapies that can cross the blood-brain barrier, an essential obstacle in the treatment of central nervous system diseases. Based in South San Francisco, California, Denali Therapeutics is at the forefront of the biotech industry, collaborating with research institutions and other pharmaceutical companies to advance its pipeline of potential treatments. Its work is pivotal in addressing unmet medical needs related to neurodegeneration, positioning the company as an important player in the pursuit of innovative healthcare solutions aimed at improving the quality of life for affected patients.
About
CEO
Dr. Ryan J. Watts Ph.D.
Employees
443
Address
161 Oyster Point Boulevard
South San Francisco, 94080, CA
United States
South San Francisco, 94080, CA
United States
Phone
650 866 8547
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNGS